Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Closed-end funds have unique features that make them very attractive investment vehicles for the right asset classes and investors who understand them. Especially for complex and/or less liquid asset ...
PHILADELPHIA, PA / ACCESSWIRE / March 21, 2024 / abrdn Healthcare Investors (NYSE:HQH), abrdn Life Sciences Investors (NYSE:HQL), abrdn Healthcare Opportunities Fund (NYSE:THQ), and abrdn World Health...
For the second consecutive month, both equity (+3.42% on a NAV basis) and fixed income (+3.14%) CEFs on average posted plus-side returns. At month end, 9% of all CEFs traded at a premium to their NAV,...
PHILADELPHIA, PA / ACCESSWIRE / November 9, 2023 / The following abrdn U.S. Closed-End Funds announced today that the closed end funds in the chart directly below will pay the distributions indicated ...
PHILADELPHIA, PA / ACCESSWIRE / October 27, 2023 / Effective close of business today, October 27, 2023, abrdn Inc. ("abrdn") assumed responsibility for the management of the four (4) former Tekla Capi...
Tekla Capital Management LLC (Tekla) announced today that it has completed the sale of its advisory business to abrdn Inc. In addition, effective close of regular business, abrdn was approved as manag...
BOSTON--(BUSINESS WIRE)--Tekla Capital Management LLC (Tekla) announced today that the requisite vote has been attained to approve the new investment advisory agreement with abrdn Inc. for each of its...
BOSTON--(BUSINESS WIRE)--On September 29, 2023, Tekla Life Sciences Investors paid a distribution of $0.32 per share. It is currently estimated that this distribution is derived from net realized long...
Tekla Life Sciences Investors invests primarily in biotechnology stocks, and 10-12 large-cap biotech stocks (50% of total holdings) sets the trend and price direction for this fund. Poor price growth ...
